Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial

Vaccine

Volumn 31, Issue 48, 2013, Pages 5680-5686

  Boffito, Marta ^a   Fox, Julie ^b   Bowman, Christine ^c   Fisher, Martin ^d   Orkin, Chloe ^e   Wilkins, Edmund ^f   Jackson, Akil ^a   Pleguezuelos, Olga ^g   Robinson, Stuart ^g   Stoloff, Gregory A ^g   Caparrós Wanderley, Wilson ^g  

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d Worthing Hospital   (United Kingdom)

^e ROYAL LONDON HOSPITAL   (United Kingdom)

^f NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^g SEEK   (United Kingdom)

Author keywords

CD4 count; HIV; Immunotherapy; Phase Ib clinical trial; Viral load

Indexed keywords

ANTIVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; MONTANIDE ISA 51; PLACEBO;

ABSCESS; ADULT; ARTICLE; B LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FATIGUE; GASTROENTERITIS; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOTHERAPY; INJECTION SITE PAIN; KAPOSI SARCOMA; LOWER ABDOMINAL PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERINANAL ABSCESS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHIGELLOSIS; T LYMPHOCYTE; VIRUS LOAD;

CD4 COUNT; HIV; IMMUNOTHERAPY; PHASE IB CLINICAL TRIAL; VIRAL LOAD;

ADOLESCENT; ADULT; AIDS VACCINES; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PLACEBOS; VIRAL LOAD; YOUNG ADULT;

EID: 84886950797     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.057     Document Type: Article

References (40)

1. Nachega J.B., Marconi V.C., van Zyl G.U., Gardner E.M., Preiser W., Hong S.Y., et al. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets 2011, 11(2):167-174.
2. Carr A., Cooper D.A. Adverse effects of antiretroviral therapy. Lancet 2000, 356(9239):1423-1430.
3. Pett S.L. Immunotherapies in HIV-1 infection. Curr Opin HIV AIDS 2009, 4(3):188-193.
4. Weber R., Bossart W., Cone R., Luethy R., Moelling K. Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects. Eur J Clin Microbiol Infect Dis 2001, 20(11):800-803.
5. Spearman P., Lally M.A., Elizaga M., Montefiori D., Tomaras G.D., McElrath M.J., et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis 2011, 203(8):1165-1173.
6. Connor R.I., Korber B.T., Graham B.S., Hahn B.H., Ho D.D., Walker B.D., et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol 1998, 72(2):1552-1576.
7. Mascola J.R., Snyder S.W., Weislow O.S., Belay S.M., Belshe R.B., Schwartz D.H., et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1 The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996, 173(2):340-348.
8. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, Placebo-controlled, test-of-concept trial. Lancet 2008, 372(9653):1881-1893.
9. Watkins D.I., Burton D.R., Kallas E.G., Moore J.P., Koff W.C. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008, 14:617-621.
10. Plummer F.A., Ball T.B., Kimani J., Fowke K.R. Resistance to HIV-1 infection among highly exposed sex workers in Nairobi: what mediates protection and why does it develop?. Immunol Lett 1999, 66(1-3):27-34.
11. Kaul R., Plummer F.A., Kimani J., Dong T., Kiama P., Rostron T., et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 2000, 164(3):1602-1611.
12. Mendoza D., Johnson S.A., Peterson B.A., Natarajan V., Salgado M., Dewar R.L., et al. Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood 2012, 119(20):4645-4655.
13. Altfeld M., Allen T.M. Hitting HIV where it hurts: an alternative approach to HIV vaccine design. Trends Immunol 2006, 27(11):504-510.
14. Korber B., Gaschen B., Yusim K., Thakallapally R., Kesmir C., Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001, 58:19-42.
15. Pleguezuelos O., Stoloff G.A., Caparros-Wanderley W. Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation. Virol J 2013, 10(107.).
16. Chenna R., Sugawara H., Koike T., Lopez R., Gibson T.J., Higgins D.G., et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 2003, 31(13):3497-3500.
17. Stoloff G.A., Caparrós-Wanderley W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur J Immunol 2007, 37:2441-2449.
18. Leroux-Roels G., Maes C., Clement F., van Engelenburg F., van den Dobbelsteen M., Adler M., et al. Randomized phase I: safety immunogenicity and mucosal antiviral activity in young healthy women vaccinated with HIV-1 Gp41 P1 peptide on virosomes. PLoS ONE 2013, 8(2):e55438. 10.1371/journal.pone.0055438.
19. Lind A., Sommerfelt M., Holmberg J.O., Baksaas I., Sørensen B., Kvale D. Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4+ and CD8+ T cell responses lasting more than seven years. Scand J Infect Dis 2012, 44(8):566-572.
20. Cobb A., Roberts L.K., Palucka A.K., Mead H., Montes M., Ranganathan R., et al. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. J Immunol Methods 2011, 365(1/2):27-37.
21. Leroux-Roels I., Koutsoukos M., Clement F., Steyaert S., Janssens M., Bourguignon P., et al. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine 2010, 28(43):7016-7024.
22. Graham B.S., McElrath M.J., Keefer M.C., Rybczyk K., Berger D., Weinhold K.J., et al. AIDS Vaccine Evaluation Group Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS ONE 2010, 5(8):e11995.
23. Spearman P., Kalams S., Elizaga M., Metch B., Chiu Y.L., Allen M., et al. NIAID HIV Vaccine Trials Network. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine 2009, 27(2):243-249.
24. Gahéry-Ségard H., Pialoux G., Figueiredo S., Igéa C., Surenaud M., Gaston J., et al. Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized. J Virol 2003, 77(20):11220-11231.
25. Toledo H., Baly A., Castro O., Resik S., Laferté J., Rolo F., et al. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 2001, 19(30):4328-4336.
26. Siegrist C.A. Vaccine immunology. Vaccines 2012, 17-36. Elsevier, Philadelphia, PA. 6th ed. S. Plotkin, W. Orenstein, P. Offit (Eds.).
27. Pleguezuelos O., Robinson S., Stoloff G.A., Caparrós-Wanderley W. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial. Vaccine 2012, 30(31):4655-4660.
28. Wu Y., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 2008, 3(7):2636.
29. Vaccine administration guidelines Epidemiology and prevention of vaccine-preventable diseases (The Pink Book) 2012, Centers for Disease Control and Prevention, Public Health Foundation, Washington, DC, [appendix D]. 12th ed., second printing. W. Atkinson, S. Wolfe, J. Hamborsky (Eds.).
30. Yamada T., Iwamoto A. Expression of a novel Nef epitope on the surface of HIV type 1-infected cells. AIDS Res Hum Retroviruses 1999, 15:1001-1009.
31. Yamada T., Watanabe N., Nakamura T., Iwamoto A. Antibody-dependent cellular cytotoxicity via humoral immune epitope of Nef protein expressed on cell surface. J Immunol 2004, 172:2401-2406.
32. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med 2009, 361:2209-2220.
33. Puppo F., Brenci S., Bosco O., Lanza L., Barocci S., Nocera A., et al. Downregulation of HLA class I antigen expression in CD4+ T lymphocytes from HIV type 1-infected individuals. AIDS Res Hum Retroviruses 1997, 13(17):1509-1516.
34. Addo M.M., Yu X.G., Rathod A., Cohen D., Eldridge R.L., Strick D., et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003, 77(3):2081-2092.
35. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007, 13(1):46-53.
36. Olivieri K.C., Mukerji J., Gabuzda D. Nef-mediated enhancement of cellular activation and human immunodeficiency virus type 1 replication in primary T cells is dependent on association with p21-activated kinase 2. Retrovirology 2011, 8:64.
37. Gabuzda D.H., Li H., Lawrence K., Vasir B.S., Crawford K., Langhoff E. Essential role of vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/macrophages. J Acquir Immune Defic Syndr 1994, 7(9):908-915.
38. Demberg T., Florese R.H., Gomez-Roman V.R., Larsen K., Van Rompay K.K.A., Marthas M.L., et al. Non-neutralizing antibodies and vaccine-induced protection. Retrovirology 2006, 3(Suppl. 1):S26.
39. Marconi V.C., Grandits G., Okulicz J.F., Wortmann G., Ganesan A., Crum-Cianflone N., et al. Cumulative Viral Load and Virologic Decay Patterns after Antiretroviral Therapy in HIV-Infected Subjects Influence CD4 Recovery and AIDS. PLoS ONE 2011, 6(5):e17956.
40. Gross national income per capita, World Bank. Available at: [accessed 22.05.13]. http://data.worldbank.org/indicator/NY.GNP.PCAP.CD.